Diffuse intrinsic pontine glioma (DIPG) is a rare, aggressive neuroglial tumor arising from the pons of the brainstem. Per Orphanet (Orphanet:497188), the condition primarily affects children and carries a poor prognosis. DIPG is also referred to as diffuse midline glioma and infiltrative brainstem glioma. A recognized subtype is diffuse midline glioma, H3 K27-altered (MONDO:1060171).

Detailed phenotype frequency data are not enumerated in the current knowledge packet for DIPG. The tumor's brainstem location forms the anatomical basis for the neurological features associated with the condition; frequency-mapped symptom profiles from authoritative sources are not available in this record.

DIPG arises from glial cells in the brainstem as a somatic tumor. No germline causative gene variants are recorded in this knowledge packet, and no familial inheritance pattern has been established. Somatic molecular alterations are understood to drive tumor development; active research explores therapeutic approaches targeting specific tumor markers.

Diagnosis of DIPG relies on clinical presentation and characteristic neuroimaging findings consistent with a diffuse infiltrative pontine mass. Confirmation is established through neuro-oncology evaluation; no diagnostic genetic panel criteria are recorded in this knowledge packet.

Treatment planning for diffuse intrinsic pontine glioma depends on tumor characteristics, disease extent, and overall patient health. Management involves a multidisciplinary oncology team and may encompass local therapies such as radiation, systemic treatment approaches, and supportive care. No treatments are specifically FDA-approved for DIPG. Treatment goals are individualized and may be directed toward disease control, symptom management, or palliative care.

Orphanet records DIPG as a condition carrying a poor prognosis. Outcomes vary by tumor characteristics, response to treatment, and access to specialized oncology care. No specific survival statistics are recorded in the current knowledge packet.

DIPG is an active area of clinical investigation. Numerous clinical trials are currently underway according to ClinicalTrials.gov, evaluating approaches that include immunotherapy, vaccine-based strategies, targeted agents, and cell therapies. A substantial body of research literature has been classified, with basic science and preclinical work representing the dominant publication type.